Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC)

In the present study, we investigated the prognostic value of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 serum levels in patients with metastatic non-small cell lung cancer (NSCLC). From September 1999 to June 2001, pretreatment serum levels of VEGF and MMP-9 were...

Full description

Saved in:
Bibliographic Details
Published in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2005-10, Vol.50 (1), p.51-58
Main Authors: Laack, Eckart, Scheffler, Antje, Burkholder, Iris, Boeters, Ina, Andritzky, Birte, Schuch, Gunter, Görn, Michael, Vohwinkel, Gaby, Edler, Lutz, Fiedler, Walter, Hossfeld, Dieter Kurt
Format: Article
Language:English
Subjects:
Adult
Aged
Angiogenic factors
Biological and medical sciences
Carcinoma, Non-Small-Cell Lung - pathology
Enzyme-Linked Immunosorbent Assay
Female
Follow-Up Studies
Humans
Lung Neoplasms - pathology
Male
Matrix Metalloproteinase 9 - blood
Medical sciences
Middle Aged
MMP-9
NSCLC
Pneumology
Prognosis
Prognostic factors
Survival Analysis
Tumors of the respiratory system and mediastinum
Vascular Endothelial Growth Factor A - blood
VEGF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the present study, we investigated the prognostic value of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP)-9 serum levels in patients with metastatic non-small cell lung cancer (NSCLC). From September 1999 to June 2001, pretreatment serum levels of VEGF and MMP-9 were analysed in 194 patients of a randomized phase III trial with enzyme-linked immunoassays. Patients with a VEGF serum level higher than the median serum level (10,995 pg/ml) had a significantly shorter overall survival than those with a lower serum level ( P = 0.04). The MMP-9 serum level did not correlate with survival. In a multivariate Cox regression analysis, only the pretreatment serum level of VEGF, the Karnofsky performance status, and the presence of bone metastases were identified as independent prognostic factors. The pretreatment VEGF serum level was identified as independent prognostic factor in this study and may help to assess individual risk and treatment profiles in patients with metastatic NSCLC.
ISSN:0169-5002
1872-8332
DOI:10.1016/j.lungcan.2005.05.011